A New York state Supreme Court hearing Johnson & Johnson’s appeal of a 2019 baby powder judgment has agreed to reduce a $325 million jury award by two-thirds to $120...

Johnson & Johnson is mulling whether to appeal a major financial setback in its ongoing talc baby powder litigation to the US Supreme Court.

Johnson & Johnson has temporarily paused all clinical trials of its adenovirus-based vaccine candidates, including the recently begun US Phase 3 trial, due to safety...

Through its subsidiary Janssen Pharmaceutical Companies, US healthcare giant Johnson & Johnson has agreed to provide 200 million doses of its Covid-19 vaccine to the...

Johnson & Johnson (J&J) has agreed to pay in excess of $100 million to resolve more than 1,000 class action lawsuits claiming its talc-based baby powder caused their...

With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a...

After months of uncertainty and anxious glances across the water as potential Covid-19 vaccine manufacturers made deal after deal with other political blocs, the EU over...

Johnson & Johnson has agreed to acquire autoimmune disease specialist Momenta Pharmaceuticals in an all-cash transaction of about $6.5 billion. Both companies’ boards of...